tm logo
REYULTI
ABANDONED SECTION 36

on 09 Dec 2020

Last Applicant/ Owned by

OTSUKA PHARMACEUTICAL CO. LTD.

2-9 Kanda-TsukasamachiChiyoda-ku, Tokyo

JP

Serial Number

1876729 filed on 10th Jan 2018

Correspondent Address

SUITE 1000, 55 METCALFE STREETP.O. BOX 2999, STATION DOTTAWA

ONTARIO

CA

K1P5Y6

REYULTI

Trademark usage description

pharmaceuticals and medical preparations and substances and vaccines for the prevention and treatment of disorders and diseases in, generated by and a Read More

Classification Information


Class [005]
Pharmaceuticals and medical preparations and substances and vaccines for the prevention and treatment of disorders and diseases in, generated by and acting on the central nervous system, namely, dementia, Alzheimer's disease and disorder, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, cancer, migraine, pain, alcoholism and dependency; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by and acting on the central nervous system, namely dementia, Alzheimer's disease and disorder, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, cancer, migraine, pain, alcoholism and dependency; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases, namely dementia, Alzheimer's disease and disorder, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, cancer, migraine, pain, alcoholism and dependency; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disease and disorder, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, cancer, migraine, pain, alcoholism and dependency; diagnostic reagents and agents for medical diagnostic use.


Classification kind code

11

Mark Details


Serial Number

1876729

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 67
on 11th Sep 2019
Agent Name Changed
Submitted for opposition 26
on 29th Aug 2019
Approved
Submitted for opposition 27
on 29th Aug 2019
Approval Notice Sent
Submitted for opposition 48
on 30th Jul 2019
Agent Changed
Submitted for opposition 80
on 30th Jul 2019
Change of Title Registered
Submitted for opposition 22
on 10th Jan 2019
Search Recorded
Submitted for opposition 20
on 10th Jan 2019
Examiner's First Report
Submitted for opposition 31
on 15th Jan 2018
Formalized
Submitted for opposition 30
on 10th Jan 2018
Filed
Submitted for opposition 1
on 10th Jan 2018
Created